Kissei Pharmaceutical Co (4547) AI Stock Analysis

• Market Cap: $177.31B
• Dividend Yield: 2.14%
• Average Volume (3M): 111.31K
• Price to Earnings (P/E): 15.3
• Beta (1Y): 0.51
• Revenue Growth: 16.87%
• EPS Growth: 11.20%
• Country: JP
• Employees: 1,779
• Sector: Healthcare
• Sector Strength: 53
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 72.81
• Shares Outstanding: 47,911,186
• 10 Day Avg. Volume: 84,130
• 30 Day Avg. Volume: 111,310
• PEG Ratio: -0.67
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 27.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4,949.91
• Price Target Upside: 19.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 75 Outperform
• Price Target: ¥4,826.00 ▲(16.43%Upside)

Kissei Pharmaceutical is rated positively due to its strong financial performance and robust technical indicators. The stock is fairly valued, supported by a stable P/E ratio and dividend yield. Despite no current earnings call or corporate event insights, the company's fundamentals remain solid.

Kissei Pharmaceutical Co Business Overview & Revenue Model

Company Description

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.

How the Company Makes Money

Kissei Pharmaceutical Co generates revenue primarily through the sale of its pharmaceutical products, both domestically in Japan and internationally. The company's revenue streams include the commercialization of proprietary drugs, licensing agreements, and partnerships with other pharmaceutical companies for co-development and distribution. Key factors contributing to its earnings include successful product launches, regulatory approvals, and strategic collaborations that expand its market reach and enhance its product portfolio.

Kissei Pharmaceutical Co Financial Statement Overview

Summary

Kissei Pharmaceutical shows strong financial performance with robust revenue growth, stable margins, and solid profitability. The balance sheet is stable with low leverage and strong equity. Cash flow improvements are notable, but further enhancement in free cash flow relative to income is needed.

Income Statement

Kissei Pharmaceutical experienced robust revenue growth from 2024 to 2025 with a growth rate of 16.85%. The gross profit margin remained stable at around 49.9%, while the net profit margin improved to 13.54%. EBIT and EBITDA margins indicate strong operational efficiency, with a noticeable recovery in EBIT margin to 6.54% after a prior negative performance. Overall, the company shows solid profitability and growth trajectory despite past volatility.

Balance Sheet

The balance sheet reflects financial stability with a low debt-to-equity ratio of 0.0061 and a high equity ratio of 85.63%. Return on equity is commendable at 5.72%, highlighting effective use of shareholders' equity. These metrics indicate strong financial health and low leverage, providing a cushion against market fluctuations.

Cash Flow

Cash flows have improved significantly, with a positive shift in free cash flow and operating cash flow from previous negative values. The operating cash flow to net income ratio is 0.55, showcasing a decent conversion of income to cash. However, the free cash flow to net income ratio remains low at 0.17, suggesting room for improvement in cash generation relative to net income.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
71.30B	88.33B	75.58B	67.49B	65.38B	69.04B
	Gross Profit
47.72B	44.06B	37.34B	32.38B	31.24B	32.72B
	EBIT
10.27B	5.77B	4.02B	-1.13B	-1.40B	1.50B
	EBITDA
11.60B	20.25B	18.72B	17.81B	20.26B	10.65B
	Net Income Common Stockholders
8.16B	11.96B	11.16B	10.53B	12.92B	5.29B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
43.20B	48.65B	45.93B	49.60B	53.15B	44.45B
	Total Assets
228.45B	244.06B	260.93B	221.20B	238.09B	268.86B
	Total Debt
1.39B	1.28B	1.34B	1.49B	1.64B	1.74B
	Net Debt
-18.52B	-23.89B	-21.55B	-24.40B	-28.37B	-18.71B
	Total Liabilities
30.86B	33.93B	39.80B	26.39B	35.91B	48.91B
	Stockholders Equity
196.55B	209.00B	220.03B	193.90B	201.38B	219.31B
Cash Flow		Free Cash Flow
0.00	2.01B	-3.51B	-9.23B	-386.00M	-4.03B
	Operating Cash Flow
0.00	6.52B	-1.68B	-6.68B	1.53B	-2.54B
	Investing Cash Flow
0.00	4.95B	8.69B	6.00B	10.78B	-9.33B
	Financing Cash Flow
0.00	-9.32B	-10.01B	-3.42B	-2.76B	-4.00B

Kissei Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4145.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4547, the sentiment is Positive. The current price of 4145 is above the 20-day moving average (MA) of 4097.25, above the 50-day MA of 3898.80, and above the 200-day MA of 3719.17, indicating a bullish trend. The MACD of 85.75 indicates Positive momentum. The RSI at 57.10 is Neutral, neither overbought nor oversold. The STOCH value of 29.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4547.

Kissei Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4547	75 Outperform	$177.31B	15.32	5.47%	2.14%	16.87%	11.20%
Sector *	54 Neutral	$5.34B	3.36	-45.10%	3.39%	16.81%	-0.03%
KKPCF		$959.25M	11.14	9.44%	0.03%	―	―
TRXPF		$1.23B	28.25	4.56%	2.30%	―	―
TWAPF		$1.01B	10.01	11.38%	0.01%	―	―
MFY		€602.73M	17.76	4.35%	2.84%	―	―
4887	69 Neutral	¥180.58B	9.82		2.96%	-3.69%	76.69%

Kissei Pharmaceutical Co Corporate Events

Kissei Pharmaceutical Reports Strong Fiscal 2024 Performance with Strategic Market Expansion

Kissei Pharmaceutical Co reported a significant financial performance for Fiscal 2024, with net sales reaching ¥88,330 million, marking a 16.9% increase year-over-year, and an operating profit of ¥5,773 million, a 43.7% rise. The growth was driven by increased sales in both domestic and international markets, particularly through the expansion of products like Linzagolix and Fostamatinib. The company also saw a rise in R&D expenses due to new product developments and licensing agreements, indicating a strategic focus on innovation and market expansion.

Kissei Pharmaceutical Completes Treasury Share Acquisition and Plans Cancellation

Kissei Pharmaceutical Co., Ltd. has completed the acquisition of 1,369,200 treasury shares, representing 3.20% of its issued shares, for a total cost of 5,216,652,000 yen. This move is part of a flexible capital policy aimed at improving capital efficiency and enhancing shareholder returns, with the acquired shares set to be canceled by June 27, 2025.

Kissei Pharmaceutical Reports Strong Fiscal Year Performance and Plans for Growth

Kissei Pharmaceutical Co., Ltd. reported a significant increase in its financial performance for the fiscal year ended March 31, 2025, with net sales rising by 16.9% and operating profit increasing by 43.7%. The company plans to enhance shareholder value through a treasury share purchase and forecasts continued growth in the upcoming fiscal year.

Kissei Pharmaceutical Announces Treasury Share Acquisition and Cancellation

Kissei Pharmaceutical Co., Ltd. has announced a strategic move to acquire and subsequently cancel a portion of its treasury shares. This decision, approved by the Board of Directors, aims to improve capital efficiency and enhance shareholder returns, reflecting the company’s adaptive capital policy in response to market conditions.

Kissei Pharmaceutical Revamps Executive Compensation System

Kissei Pharmaceutical Co., Ltd. announced a revision to its executive compensation system, aiming to align director incentives with the company’s sustainable growth and long-term value creation goals. This revision, subject to shareholder approval, introduces a new compensation structure that includes base salary, performance-linked bonuses, and restricted stock compensation, reflecting a strategic shift to enhance corporate governance and stakeholder value.

Kissei Pharmaceutical Co. Increases Year-End Dividend Amid Growth Strategy

Kissei Pharmaceutical Co. announced an increase in its year-end dividend to ¥55 per share, reflecting a ¥10 rise from the previous forecast, resulting in an annual dividend of ¥100 per share. This decision is part of the company’s new mid-term management plan, ‘Beyond 80,’ which emphasizes shareholder returns, including a planned allocation of 57 billion yen for dividends and share buybacks over the next five years.

Kissei Pharmaceutical Unveils Ambitious ‘Beyond 80’ Growth Plan

Kissei Pharmaceutical has announced its new five-year management plan, ‘Beyond 80,’ which aims to build on the successes of its previous plan, PEGASUS. The company exceeded its sales targets in 2024 and plans to continue its growth by expanding its R&D pipeline, launching new products, and increasing its international presence. The ‘Beyond 80’ plan focuses on sustainable growth, environmental management, and achieving significant financial metrics, such as an ROE of over 8% and a 10-year average growth rate of over 5% in sales.